Arovella Therapeutics Ltd
ASX:ALA

Watchlist Manager
Arovella Therapeutics Ltd Logo
Arovella Therapeutics Ltd
ASX:ALA
Watchlist
Price: 0.086 AUD -5.49%
Market Cap: 101.8m AUD

Net Margin
Arovella Therapeutics Ltd

-1 416.4%
Current
-5 450%
Average
5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 416.4%
=
Net Income
-6.3m
/
Revenue
442.1k

Net Margin Across Competitors

Country Company Market Cap Net
Margin
AU
Arovella Therapeutics Ltd
ASX:ALA
101.8m AUD
-1 416%
US
Eli Lilly and Co
NYSE:LLY
750.6B USD
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
379.3B USD
24%
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK
35%
CH
Roche Holding AG
SIX:ROG
209.2B CHF
14%
CH
Novartis AG
SIX:NOVN
194.4B CHF
24%
UK
AstraZeneca PLC
LSE:AZN
164.8B GBP
14%
US
Merck & Co Inc
NYSE:MRK
212.2B USD
27%
IE
Endo International PLC
LSE:0Y5F
184.8B USD
-126%
US
Pfizer Inc
NYSE:PFE
146.7B USD
13%

Arovella Therapeutics Ltd
Glance View

Market Cap
101.8m AUD
Industry
Pharmaceuticals

Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-01-24. The firm focuses on specific disease areas, oncology and conditions that affect the central nervous system. The company is focused on developing therapies to treat human disease. The firm is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The firm's OroMist technology develops oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. The company is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

ALA Intrinsic Value
0.006 AUD
Overvaluation 93%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 416.4%
=
Net Income
-6.3m
/
Revenue
442.1k
What is the Net Margin of Arovella Therapeutics Ltd?

Based on Arovella Therapeutics Ltd's most recent financial statements, the company has Net Margin of -1 416.4%.

Back to Top